TIDMIMM

RNS Number : 0704G

Immupharma PLC

01 November 2018

1 November 2018

ImmuPharma PLC

("ImmuPharma" or the "Company")

Nominated Adviser Status

ImmuPharma PLC (AIM: IMM.L), the specialist drug discovery and development company, announces that the Directors are aware of the proposed merger of its current nominated adviser ("NOMAD"), Northland Capital Partners ("Northland") with SP Angel Corporate Finance LLP. The Directors have also been informed that Northland has voluntarily agreed to relinquish its NOMAD status and will be removed from the register of NOMADs with effect from 7am (GMT) on 1 February 2019.

In accordance with AIM Rule 1, the Company is required to appoint a new NOMAD by 1 February 2019, if not, the Exchange will suspend trading in the Company's AIM Securities. If the Company does not appoint a replacement NOMAD by 4 March 2019, the admission of its AIM Securities will be cancelled.

The Company has commenced the process to appoint a new NOMAD and will make a further announcement in due course.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

 
 For further information please contact: 
                                                        + 44 (0) 20 
   ImmuPharma plc (www.immupharma.co.uk)                 7152 4080 
   Tim McCarthy, Chairman 
                                                        + 44 (0) 7721 
   Lisa Baderoon, Head of Investor Relations             413496 
   Northland Capital Partners Limited (NOMAD & Joint    +44 (0)20 3861 
    Broker)                                              6625 
    David Hignell, Dugald Carlean, Jamie Spotswood, 
    Corporate Finance 
    Rob Rees, Corporate Broking 
 
    Stanford Capital Partners (Joint Broker)             +44 (0) 20 
    Patrick Claridge                                     3815 8880 
    Chris Coleman 
 
    SI Capital (Joint Broker)                            +44 (0) 1483 
    Nick Emerson                                         413500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCUGGQWGUPRGWG

(END) Dow Jones Newswires

November 01, 2018 09:38 ET (13:38 GMT)

Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Immupharma Charts.
Immupharma (LSE:IMM)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Immupharma Charts.